Table 2.
Diagnostic or prognostic value of NNT-AS1 expression.
| Cancer Type | Sample Size | Expression Pattern | Diagnostic/Prognostic Value | Ref. |
|---|---|---|---|---|
| NSCLC | 37 patients | Up-regulated | Prognostic factor of OS | [17] |
| Gastric cancer | 30 patients | Down-regulated | AUC = 0.63, sensitivity = 73.3%, specificity = 70% | [34] |
| 48 patients | Up-regulated | Prognostic factor of OS | [32] | |
| CRC | 70 patients | Up-regulated | Independent prognostic factor of OS and PFS | [14] |
| HCC | 42 patients | Up-regulated | Prognostic factor of OS | [21] |
| Cholangiocarcinoma | 48 patients | Up-regulated | Prognostic factor of OS | [22] |
| 30 patients | Up-regulated | Prognostic factor of OS and DFS | [24] | |
| Cervical cancer | 79 patients | Up-regulated | Prognostic factor of OS | [25] |
| 58 patients | Up-regulated | Prognostic factor of OS | [26] | |
| Breast cancer | 64 patients | Up-regulated | Independent prognostic factor of OS | [36] |
| 54 patients | Down-regulated | AUC not shown, specificity = 71.2%, sensitivity = 56.6% | [37] | |
| Bladder cancer | 47 patients | Up-regulated | Prognostic factor of OS | [30] |
| Osteosarcoma | 126 patients | Up-regulated | Prognostic factor of OS and DFS | [27] |
NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; HCC, hepatocellular carcinoma; OS, overall survival; AUC, area under the curve; PFS, progression-free survival; DFS, disease free survival.